Clinical and endoscopic parameters at presentation that predict the need for long-term immunosuppression in ulcerative colitis

Abstract

Introduction: The clinical course of ulcerative colitis (UC) ranges from a mild course with prolonged periods of remission to severe disease requiring long-term immunosuppression for disease control. There is limited data on the predictors of need for immunosuppression at presentation. Objective: The aim was to evaluate clinical, endoscopic and histopathological parameters at presentation in patients with UC that predict the need for long-term immunosuppressive therapy. Materials and Methods: We studied 81 patients (males; 40; mean age 38.69 ± 12.90 years) with UC (41 prospectively and 40 retrospectively). The clinical presentation, duration, extra-intestinal features, extent of disease, haematological and biochemical features, histology and outcome (drugs, surgery, and mortality) were recorded and analyzed. Subgroup analysis was done after dividing the patients into two groups depending upon whether they needed long term immunosuppressants or not. Results: The presenting symptoms were bloody stools (100%), mucus in stools (98.8%), abdominal pain (35.8%), anorectal pain (14.8%) and extra-intestinal symptoms (4.9%). Of these 81 patients, 7 (8.6%) patients required surgery and 2 (2.4%) patients died. Long term immunosuppressants were used in 19 patients (Azathioprine 16, Mycophenolate mofetil 2 and Tacrolimus 1). The patients who received immunosuppressants had a higher prevalence of pancolitis (47.4% vs. 16.1%, P = 0.005). Other clinical, hematological and histological parameters such as inflammatory grade, chronicity grade, cellular infiltrates, submucosal fibrosis, Paneth cell metaplasia, and the presence of neuronal cells were similar in the two groups. Conclusion: Of the clinical, biochemical, endoscopic and histological features at presentation only the presence of pancolitis predicts the need for long term immunosuppressants in ulcerative colitis.

Key words

Colonoscopy - immunosuppression - pancolitis - ulcerative colitis

• References

• 1 Sachar DB, Lemmer E, Ibrahim C, Edden Y, Ullman T, Ciardulo J, et al. Recurrence patterns aft er first resection for stricturing or penetrating Crohn’s disease. Inflamm Bowel Dis 2009;15:1071-5.
• 2 Tremaine WJ, Sandborn WJ, Loft us EV, Kenan ML, Petterson TM, Zinsmeister AR, et al. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol 2001;96:2401-6.
• 3 Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993;28:821-6.
• 4 Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962;2:441-3.
• 5 Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial. Br Med J 1974;4:627-30.
• 6 Gupta S, Keshavarzian A, Hodgson HJ. Cyclosporin in ulcerative colitis. Lancet 1984;2:1277-8.
• 7 Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002;8:317-24.
• 8 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
• 9 Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, et al. Infliximab in severe ulcerative colitis: Short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26:747-56.
• 10 Yang SK, Loft us EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001;7:260-70.
• 11 Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis 2007;13:278-83.
• 12 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
• 13 Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northeastern Scotland: A community study. Gastroenterology 1983;85:1-11.
• 14 Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: A prospective study. Saudi J Gastroenterol 2011;17:194-8.
• 15 Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990;31:179-83.
• 16 Leo S, Leandro G, Di Matteo G, Caruso ML, Lorusso D. Ulcerative colitis in remission: It is possible to predict the risk of relapse? Digestion 1989;44:217-21.
• 17 Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
• 18 Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
• 19 Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012;107:1684-92.
• 20 Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet 1978;1:1140-3.
• 21 Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: Results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40.
• 22 Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: A case-control study. Aliment Pharmacol Ther 2008;28:606-13.